

## NEWS RELEASE

UNDER EMBARGO UNTIL SEPTEMBER 10, 2013, 12:01 AM ET

### Contacts:

Eileen Leahy

Elsevier

Tel: 732-238-3628

[ajpmedia@elsevier.com](mailto:ajpmedia@elsevier.com)

Dr. Chhavi Chauhan

Scientific Editor

*The American Journal of Pathology*

Tel: 301-634-7953

[cchauhan@asip.org](mailto:cchauhan@asip.org)

---

## Novel Avian Influenza A Virus Has Potential for Both Virulence and Transmissibility in Humans

Virus Attaches to Both Upper and Lower Respiratory Tract Epithelium, According to Report in  
*The American Journal of Pathology*

Philadelphia, PA, September 10, 2013 – A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts. This pattern has not been observed before for avian influenza A viruses. The report, published in the October issue of *The American Journal of Pathology*, suggests that the emerging H7N9 virus has the potential to cause a pandemic, since it may transmit efficiently in humans and cause severe pneumonia.

The first report of infections of humans with the influenza A virus of the subtype H7N9 surfaced in March 2013. Three patients from eastern China developed severe pneumonia and acute respiratory distress syndrome and died as a result. By May 30, 2013, the H7N9 infection was confirmed in 132 patients from China and Taiwan, 37 of whom died, according to the World Health Organization ([http://www.who.int/influenza/human\\_animal\\_interface/influenza\\_h7n9/08\\_ReportWebH7N9Number.pdf](http://www.who.int/influenza/human_animal_interface/influenza_h7n9/08_ReportWebH7N9Number.pdf)). Infected poultry were thought to be the source of the virus.

In the current study, investigators focused on the virus' pattern of attachment in order to assess its potential transmissibility and virulence. "Abundant virus attachment to the human upper respiratory tract correlates with efficient transmissibility among humans," explains Thijs Kuiken, DVM, PhD, of the Department of Viroscience at Erasmus University Medical Centre in Rotterdam, The Netherlands. "Virus attachment to Clara cells in the bronchioles and pneumocytes and macrophages in the alveoli correlates with high virulence."

Using virus histochemical analysis, the investigators looked at the pattern of attachment of two genetically engineered emerging H7 viruses (containing the hemagglutinin (HA) of either influenza virus A/Shanghai/1/13 or A/Anhui/1/13) to fixed human respiratory tract tissues and compared the findings to attachment patterns seen with human influenza viruses with high transmissibility but low virulence (seasonal H3N2 and pandemic H1N1) and highly pathogenic avian influenza (HPAI) viruses with low transmissibility and high virulence (H5N1 and H7N7).

They found that like other avian influenza viruses, the H7N9 viruses attached more strongly to lower parts of the human respiratory tract than to upper parts. However, compared to other avian influenza viruses, the attachment to epithelial cells by H7N9 in the bronchioles and alveoli of the lung was more abundant and the viruses attached to a broader range of cell types. “These characteristics fit with increased virulence of these emerging avian H7 viruses compared to that of human influenza viruses,” says Dr. Kuiken.

A third notable finding was a more concentrated attachment of H7N9 viruses in ciliated cells of the nasal concha, trachea, and bronchi, suggesting the potential for efficient transmission among humans. “However, the fact that the emerging H7N9 virus has caused infection mainly in individual human cases suggests that it has not acquired all the necessary properties for efficient transmission among humans,” notes Dr. Kuiken.

“Our results indicate that based just on the pattern of virus attachment the H7N9 currently emerging in China has the potential both to cause severe pulmonary disease and to be efficiently transmitted among humans,” says Dr. Kuiken. He emphasizes that attachment is only the first step in the replication cycle of influenza virus in its host cell, and that other steps, as well as the host response, need to be taken into account to fully understand the potential of these emerging H7 viruses to cause an influenza pandemic.

# # #

#### **NOTES FOR EDITORS**

“Novel avian-origin influenza A (H7N9) virus attaches to epithelium in both upper and lower respiratory tract of humans,” by Debby van Riel, Lonneke M.E. Leijten, Miranda de Graaf, Jurre Y. Siegers, Kirsty R. Short, Monique I.J. Spronken, Eefje J.A. Schrauwen, Ron M.A. Fouchier, Albert D.M.E. Osterhaus, and Thijs Kuiken. (DOI: 10.1016/j.ajpath.2013.06.011). It appears in *The American Journal of Pathology*, Volume 183, Issue 4 (October 2013) published by Elsevier.

Full text of the article is available to credentialed journalists upon request; contact Eileen Leahy at 732-238-3628 or [ajpmedia@elsevier.com](mailto:ajpmedia@elsevier.com). Journalists wishing to interview the authors should contact Dr. Thijs Kuiken at +31 10-704-4066 or [t.kuiken@erasmusmc.nl](mailto:t.kuiken@erasmusmc.nl).

#### **ABOUT THE AMERICAN JOURNAL OF PATHOLOGY**

*The American Journal of Pathology* (<http://ajp.amjpathol.org>), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, *The American Journal of Pathology* is the most highly cited journal in Pathology – over 38,000 cites in 2012 – with an Impact Factor of 4.522 and Eigenfactor of 0.07599 according to the *2012 Journal Citation Reports*<sup>®</sup>, Thomson Reuters, and an H index of 181 according to the *2011 SCImago Journal and Country Rank*.

#### **ABOUT ELSEVIER**

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including *The Lancet* ([www.thelancet.com](http://www.thelancet.com)) and *Cell* ([www.cell.com](http://www.cell.com)), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)), Scopus ([www.scopus.com](http://www.scopus.com)), SciVal (<http://info.scival.com>)

Reaxys ([www.elsevier.com/reaxys](http://www.elsevier.com/reaxys)), ClinicalKey ([www.clinicalkey.com](http://www.clinicalkey.com)) and Mosby's Suite ([www.confidenceconnected.com](http://www.confidenceconnected.com)), which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ([www.elsevier.com](http://www.elsevier.com)) employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc ([www.reedelsevier.com](http://www.reedelsevier.com)), a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.